{"id":1668,"date":"2015-10-09T11:58:40","date_gmt":"2015-10-09T10:58:40","guid":{"rendered":"https:\/\/blogs.bmj.com\/heart-journalscan\/?p=1668"},"modified":"2015-11-12T17:08:52","modified_gmt":"2015-11-12T16:08:52","slug":"a-reversal-agent-for-dabigatran","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/","title":{"rendered":"A reversal agent for dabigatran"},"content":{"rendered":"<p><b><\/b><span style=\"font-weight: 400\">Unlike warfarin, non-vitamin K antagonist oral anticoagulants lack reversal agents for administration in the case of severe bleeding or perioperative management. Idarucizumab is a monoclonal antibody fragment that was developed to reverse the anticoagulant effects of the direct thrombin inhibitor dabigatran. \u00a0In this safety and efficacy study, idarucizumab was tested in a cohort of patients on dabigatran who either required an urgent surgical procedure or who had developed major bleeding. In an analysis of 90 patients (51 with hemorrhage and 39 requiring surgery) 5g of intravenous idarucizumab was administered to assess the impact on coagulation measures that included dilute thrombin time and ecarin clotting time. \u00a0Idarucizumab proved safe and effective with a median maximum percentage reversal of clotting measures of 100% within minutes of administration. Concentrations of free dabigatran remained essentially undetectable at 24 hours in 79% of patients. \u00a0Clinical hemostasis was achieved at a median of 11.4 hours in the hemorrhagic group and 3 (7.7%) patients in the surgical group had mild or moderately impaired hemostasis.<\/span><!--more--><\/p>\n<p><b>Conclusions<\/b><\/p>\n<p><span style=\"font-weight: 400\">In this small study, idarucizumab appears to rapidly reverse the anticoagulant effects of the direct thrombin inhibitor dabigatran. \u00a0Similar agents are in final stage development for both rivaroxaban and apixaban and may further improve the usability of non-vitamin K antagonist anticoagulants. <\/span><\/p>\n<p><span style=\"font-weight: 400\">Summarized by Hussain Contractor and Steven M. Bradley<\/span><\/p>\n<p><span style=\"font-weight: 400\">Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz J. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015 Aug 6;373(6):511-20. <\/span><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Unlike warfarin, non-vitamin K antagonist oral anticoagulants lack reversal agents for administration in the case of severe bleeding or perioperative management. Idarucizumab is a monoclonal antibody fragment that was developed to reverse the anticoagulant effects of the direct thrombin inhibitor dabigatran. \u00a0In this safety and efficacy study, idarucizumab was tested in a cohort of patients [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":192,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[279],"tags":[],"class_list":["post-1668","post","type-post","status-publish","format-standard","hentry","category-general-cardiology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A reversal agent for dabigatran - Heart<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A reversal agent for dabigatran - Heart\" \/>\n<meta property=\"og:description\" content=\"Unlike warfarin, non-vitamin K antagonist oral anticoagulants lack reversal agents for administration in the case of severe bleeding or perioperative management. Idarucizumab is a monoclonal antibody fragment that was developed to reverse the anticoagulant effects of the direct thrombin inhibitor dabigatran. \u00a0In this safety and efficacy study, idarucizumab was tested in a cohort of patients [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/\" \/>\n<meta property=\"og:site_name\" content=\"Heart\" \/>\n<meta property=\"article:published_time\" content=\"2015-10-09T10:58:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2015-11-12T16:08:52+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2015\\\/10\\\/09\\\/a-reversal-agent-for-dabigatran\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2015\\\/10\\\/09\\\/a-reversal-agent-for-dabigatran\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"A reversal agent for dabigatran\",\"datePublished\":\"2015-10-09T10:58:40+00:00\",\"dateModified\":\"2015-11-12T16:08:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2015\\\/10\\\/09\\\/a-reversal-agent-for-dabigatran\\\/\"},\"wordCount\":260,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\"},\"articleSection\":[\"General cardiology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2015\\\/10\\\/09\\\/a-reversal-agent-for-dabigatran\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2015\\\/10\\\/09\\\/a-reversal-agent-for-dabigatran\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2015\\\/10\\\/09\\\/a-reversal-agent-for-dabigatran\\\/\",\"name\":\"A reversal agent for dabigatran - Heart\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#website\"},\"datePublished\":\"2015-10-09T10:58:40+00:00\",\"dateModified\":\"2015-11-12T16:08:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2015\\\/10\\\/09\\\/a-reversal-agent-for-dabigatran\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2015\\\/10\\\/09\\\/a-reversal-agent-for-dabigatran\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2015\\\/10\\\/09\\\/a-reversal-agent-for-dabigatran\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A reversal agent for dabigatran\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\",\"name\":\"Heart\",\"description\":\"Highlighted articles from non-cardiological journals relevant to cardiology\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\",\"name\":\"Heart\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/files\\\/2017\\\/11\\\/blog-logo-heart.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/files\\\/2017\\\/11\\\/blog-logo-heart.png\",\"width\":145,\"height\":34,\"caption\":\"Heart\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/author\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A reversal agent for dabigatran - Heart","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/","og_locale":"en_US","og_type":"article","og_title":"A reversal agent for dabigatran - Heart","og_description":"Unlike warfarin, non-vitamin K antagonist oral anticoagulants lack reversal agents for administration in the case of severe bleeding or perioperative management. Idarucizumab is a monoclonal antibody fragment that was developed to reverse the anticoagulant effects of the direct thrombin inhibitor dabigatran. \u00a0In this safety and efficacy study, idarucizumab was tested in a cohort of patients [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/","og_site_name":"Heart","article_published_time":"2015-10-09T10:58:40+00:00","article_modified_time":"2015-11-12T16:08:52+00:00","twitter_card":"summary_large_image","twitter_misc":{"Written by":"","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/"},"author":{"name":"","@id":""},"headline":"A reversal agent for dabigatran","datePublished":"2015-10-09T10:58:40+00:00","dateModified":"2015-11-12T16:08:52+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/"},"wordCount":260,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/heart\/#organization"},"articleSection":["General cardiology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/","url":"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/","name":"A reversal agent for dabigatran - Heart","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/heart\/#website"},"datePublished":"2015-10-09T10:58:40+00:00","dateModified":"2015-11-12T16:08:52+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/heart\/2015\/10\/09\/a-reversal-agent-for-dabigatran\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/heart\/"},{"@type":"ListItem","position":2,"name":"A reversal agent for dabigatran"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/heart\/#website","url":"https:\/\/blogs.bmj.com\/heart\/","name":"Heart","description":"Highlighted articles from non-cardiological journals relevant to cardiology","publisher":{"@id":"https:\/\/blogs.bmj.com\/heart\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/heart\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/heart\/#organization","name":"Heart","url":"https:\/\/blogs.bmj.com\/heart\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/heart\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/heart\/files\/2017\/11\/blog-logo-heart.png","contentUrl":"https:\/\/blogs.bmj.com\/heart\/files\/2017\/11\/blog-logo-heart.png","width":145,"height":34,"caption":"Heart"},"image":{"@id":"https:\/\/blogs.bmj.com\/heart\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blogs.bmj.com\/heart\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts\/1668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/users\/192"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/comments?post=1668"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts\/1668\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/media?parent=1668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/categories?post=1668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/tags?post=1668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}